{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.158","value":"-6.40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"description":"The AdvSM-SAF is a 10-item questionnaire that assesses eight symptoms specific to AdvSM. All eight symptoms are scored on a scale of 0 (absence of symptoms) to 10 (more severe symptoms) (up to 80 points maximum). Each symptom contributes to the TSS equally. The TSS was generated based on average scores for each 7-day period. An increase in score from 0 (no symptoms) to 80 (worst symptoms represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an electronic diary (eDiary). Each cycle is 28 days long.","dispersionType":"Standard Deviation","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"MEAN","populationDescription":"Safety Population: all participants who received ≥1 dose of avapritinib. Here, 'Number of Participants Analyzed' signifies those participants evaluable for this outcome measure at the specified timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline up to Month 6 (Cycle 6, Day 1)","title":"Mean Change From Baseline in Advanced Systemic Mastocytosis-Symptom Assessment Form (AdvSM-SAF) Total Symptom Score (TTS)","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}